BR0308737A - Pró-drogas de fosfato de fluoroxindóis - Google Patents

Pró-drogas de fosfato de fluoroxindóis

Info

Publication number
BR0308737A
BR0308737A BR0308737-9A BR0308737A BR0308737A BR 0308737 A BR0308737 A BR 0308737A BR 0308737 A BR0308737 A BR 0308737A BR 0308737 A BR0308737 A BR 0308737A
Authority
BR
Brazil
Prior art keywords
fluoroxindole
phosphate prodrugs
enantiomer
phosphate
prodrugs
Prior art date
Application number
BR0308737-9A
Other languages
English (en)
Inventor
Kevin W Gillman
Piyasena Hewawasam
William D Schmitz
Omar D Lopez
John E Starrett
David P Provencal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0308737A publication Critical patent/BR0308737A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PRó-DROGAS DE FOSFATO DE FLUOROXINDóIS". A presente invenção refere-se a novos derivados de fosfato tendo a Fórmula (I) geral, em que a ligação ondulada (b) representa o racemato, o enanciómero (R) ou o enanciómero (S) e A, B, R^ 1^, R^ 2^, R^ 3^, R^ 4^, m e n são como definidos aqui, ou um sal ou solvato não-tóxico, farmaceuticamente aceitável, dos mesmos, e são úteis no tratamento de distúrbios que são sensíveis à abertura dos canais de potássio.
BR0308737-9A 2002-03-20 2003-03-20 Pró-drogas de fosfato de fluoroxindóis BR0308737A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36601002P 2002-03-20 2002-03-20
PCT/US2003/008613 WO2003080047A1 (en) 2002-03-20 2003-03-20 Phosphate prodrugs of fluorooxindoles

Publications (1)

Publication Number Publication Date
BR0308737A true BR0308737A (pt) 2005-01-11

Family

ID=28454740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308737-9A BR0308737A (pt) 2002-03-20 2003-03-20 Pró-drogas de fosfato de fluoroxindóis

Country Status (21)

Country Link
US (1) US6930100B2 (pt)
EP (1) EP1485085A4 (pt)
JP (1) JP4359150B2 (pt)
KR (1) KR100951499B1 (pt)
CN (1) CN100384820C (pt)
BR (1) BR0308737A (pt)
CA (1) CA2479256A1 (pt)
CO (1) CO5611143A2 (pt)
GE (1) GEP20074230B (pt)
HR (1) HRP20040853A2 (pt)
IL (2) IL164022A0 (pt)
IS (1) IS7456A (pt)
MX (1) MXPA04008999A (pt)
NO (1) NO20044442L (pt)
NZ (1) NZ535365A (pt)
PL (1) PL372413A1 (pt)
RS (1) RS81904A (pt)
RU (1) RU2312857C2 (pt)
UA (1) UA77296C2 (pt)
WO (1) WO2003080047A1 (pt)
ZA (1) ZA200407337B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
DK1856135T3 (da) 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090114877A1 (en) * 2005-09-13 2009-05-07 Eisai R&D Management Co., Ltd. Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TW200841879A (en) * 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8080544B2 (en) * 2008-02-05 2011-12-20 Merck Sharp & Dohme Corp. Prodrugs of CGRP receptor antagonists
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
WO2010151711A1 (en) * 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
PL2445502T5 (pl) 2009-06-25 2023-03-13 Alkermes Pharma Ireland Limited Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych
ES2691671T3 (es) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
WO2017007689A1 (en) 2015-07-06 2017-01-12 Gilead Sciences, Inc. Cot modulators and methods of use thereof
TWI820077B (zh) 2018-01-05 2023-11-01 美商斯布雷克薩一號公司 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
JP2021517164A (ja) * 2018-03-05 2021-07-15 テオン セラピューティクス，インク． アデノシン受容体アンタゴニストおよびその使用
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
AU2021245924B2 (en) 2020-04-02 2024-02-29 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5187173A (en) * 1991-12-27 1993-02-16 Sterling Winthrop Inc. 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
EP1051181B1 (en) 1997-12-31 2004-03-17 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
CA2318817A1 (en) * 1998-01-29 1999-08-05 Bristol-Myers Squibb Company Phosphate derivatives of diaryl 1,3,4-oxadiazolone

Also Published As

Publication number Publication date
CN100384820C (zh) 2008-04-30
JP4359150B2 (ja) 2009-11-04
PL372413A1 (en) 2005-07-25
EP1485085A1 (en) 2004-12-15
RU2004131201A (ru) 2005-05-10
RS81904A (en) 2007-02-05
IL164022A (en) 2008-04-13
AU2003215017A1 (en) 2003-10-08
KR20040106293A (ko) 2004-12-17
RU2312857C2 (ru) 2007-12-20
EP1485085A4 (en) 2007-03-14
JP2005526097A (ja) 2005-09-02
MXPA04008999A (es) 2004-12-07
IS7456A (is) 2004-09-17
ZA200407337B (en) 2006-02-22
CN1652769A (zh) 2005-08-10
CA2479256A1 (en) 2003-10-02
UA77296C2 (en) 2006-11-15
US20030195169A1 (en) 2003-10-16
HRP20040853A2 (en) 2004-12-31
US6930100B2 (en) 2005-08-16
WO2003080047A1 (en) 2003-10-02
KR100951499B1 (ko) 2010-04-07
IL164022A0 (en) 2005-12-18
CO5611143A2 (es) 2006-02-28
GEP20074230B (en) 2007-11-12
NZ535365A (en) 2006-07-28
NO20044442L (no) 2004-10-19

Similar Documents

Publication Publication Date Title
BR0308737A (pt) Pró-drogas de fosfato de fluoroxindóis
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0307998A (pt) Hidroxietilaminas substituìdas
BRPI0408561A (pt) métodos para manufatura de 2'-desoxi-59-l-nucleosìeos
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
ATE464299T1 (de) Neues phenylalaninderivat
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
HU9600834D0 (en) Quinazoline derivatives
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR0115452A (pt) Compostos tendo atividade fungicida e processos para fabricação e uso dos mesmos
BRPI0411900A (pt) compostos antivirais e métodos
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
ES2179071T3 (es) Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada.
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
NO20012567L (no) Azepinoindolderivater, fremstilling og anvendelse derav
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
EA200100678A1 (ru) N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов
ATE408601T1 (de) Fredericamycin-derivate
BR0307060A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
CY1111851T1 (el) Αρωματικες ενωσεις ως αντι-φλεγμονωδεις, ανοσορυθμιστικοι και αντι-πολλαπλασιαστικοι παραγοντες
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
DK1056754T3 (da) Phosphatderivater af diaryl-1,3,4-oxadiazolon
ES2101373T3 (es) Tetrahidrociclopent(b)indol-metaminas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/40, A61P 25/06

Ipc: A61K 31/40 (2011.01), A61P 25/06 (2011.01)

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A, 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.